Publications

Gökbuget N, Kelsh M, Chia V, Advani A, Bassan R, Dombret H, et al. 2016. Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia. Blood Cancer J 6(9):e473.

Mackay CE, Vivanco SN, Yeboah G, Vercellone J. 2016. Assessment of dermal hazard from acid burns with fire retardant garments in a full-size simulation of an engulfment flash fire. Burns 42(6):1350–1356; doi: 10.1016/j.burns.2016.04.012.

Richard A, Judson R, Houck K, Grulke C, Volarath P, Thillainadarajah I, Yang C,…, Patlewicz G, et al. 2016. The ToxCast chemical landscape: Paving the road to 21st century toxicology. Chem Res Toxicol 29(8):1225-1251; doi: 10.1021/acs.chemrestox.6b00135. PMID: 27367298.

Shah I, Liu J, Judson RS, Thomas R, Patlewicz G. 2016. Systematically evaluating read-across prediction and performance using a local validity approach characterized by chemical structure and bioactivity information. Reg Toxicol Pharmacol 79(Aug):12-24; doi: 10.1016/j.yrtph.2016.05.008. PMID: 27174420.

Thompson CM, Suh M, Mittal L, Wikoff D, Welsh B, Proctor DM. 2016. Development of linear and threshold no significant risk levels for inhalation exposure to titanium dioxide using systematic review and mode of action considerations. Regul Toxicol Pharmacol 80(Oct):60-70; doi: 10.1016/j.yrtph.2016.05.031.

Samuel GO, Hoffmann S, Wright R, Lalu MM, Patlewicz G, Becker RA, DeGeorge GL, Fergusson D, et al. 2016. Guidance on assessing the methodological and reporting quality of toxicologically relevant studies: A scoping review. Environ Int 92-93(July-Aug):630-646; doi: 10.1016/j.envint.2016.03.010. PMID: 27039952.

Jensen I, Zacherle E, Blanchette C, Zhang J, Yin W. 2016. Evaluating cost benefits of combination therapies for advanced melanoma. Drugs Context 5:212297; doi: 10.7573/dic.212297.

Wang BW, Klaren WD, Wels B, Simmons DL, Olivier AK, Wang K, Robertson LW, Ludewig G. 2016. Dietary manganese modulates PCB126 toxicity, metal status and MnSOD in the rat. Toxicol Sci 150(1):15–26; doi: 10.1093/toxsci/kfv312. PMID: 26660635.

Klaren WD, Flor SS, Gibson-Corley KN, Ludewig G, Robertson LW. 2016. Metallothionein’s role in PCB126 induced hepatotoxicity and hepatic micronutrient disruption. Toxicol Rep 3:21–28. PMID: 26770886.

Klaren WD, Gibson-Corley KN, Wels B, Simmons DL, McCormick ML, Spitz DR, Robertson LW. 2016. Assessment of the mitigative capacity of dietary zinc on PCB126 hepatotoxicity and the contribution of zinc to toxicity. Chem Res Toxicol 29(5):851–859; 10.1021/acs.chemrestox.6b00022. PMID: 26967026.

Wang A, Richhariya A, Gandra SR, Calimlim B, Quek RGW, Nordyke RJ, Toth P. 2016. Systematic review of LDL-C apheresis for the treatment of familial hypercholesterolemia. J Am Heart Assoc 5(7):e003294; doi: 10.1161/JAHA.116.003294. PMID: 27385428.

Maskrey JR, Insley A, Hynds ES, Panko JM. 2016. Air monitoring of volatile organic compounds at relevant receptors during hydraulic fracturing operations in Washington County, Pennsylvania. Environ Monit Assess 188(7):410; doi: 10.1007/s10661-016-5410-4. PMID: 27312253.

Jensen IS, Wu C, Fan W, Lodise T, Nicolau, DP, DuFour S, Cyr PL, et al. 2016. Use of oritivancin in moderate-severe ABSSSI patients requiring IV antibiotics: US hospital budget impact analysis. J Manag Care Spec Pharm 22(6):752-64; doi: 10.18553/jmcp.2016.22.6.752.

Jensen IS, Lodise TP, Fan W, Wu C, Cyr PL, Nicolau DP, DuFour S, et al. 2016. Use of oritavancin in acute bacterial skin and skin structure infection patients receiving intravenous antibiotics: A US hospital budget impact analysis. Clin Drug Investig. 2016 36(2):157-68; doi: 10.1007/s40261-015-0365-8.

Edmondson SD, Zhu C, Kar NF, Di Salvo J, Nagabukuro H, Sacre-Salem B, Dingley K, et al. 2016. Discovery of vibegron: A potent and selective beta 3 adrenergic receptor agonist for the treatment of overactive bladder. J Med Chem 59(2):609–623; doi: 10.1021/acs.jmedchem.5b01372. PMID: 26709102.

Zhu C, Kar NF, Li B, Costa M, Dingley KH, Di Salvo J, et al. 2016. Discovery of benzamides as potent human β3 adrenergic receptor agonists. Bioorg Med Chem Lett 26(1):55–59; doi: 10.1016/j.bmcl.2015.11.030. PMID: 26590100.

Wilson JE, Kurukulasuriya R, Sinz C, Matthew Lombardo, Kate Bender, Dann Parker, … Dingley K, et al. 2016. Discovery and development of benzo-[1,2,4]-triazolo-[1,4]-oxazepine GPR142 agonists for the treatment of diabetes. Bioorg Med Chem Lett 26(12):2947–2951; doi: 10.1016/j.bmcl.2016.04.018. PMID: 27240550.

Guo L, Parker DL, Zang Y, Sweis RF, Liu W, Sherer EC, … Dingley KH, et al. 2016. Discovery and optimization of a novel triazole series of GPR142 agonists for the treatment of type 2 diabetes. ACS Med Chem Lett 7 (12):1107–1111; doi: 10.1021/acsmedchemlett.6b00314. PMID: 27994747.

Pierce JS, Ruestow PS, Finley BL. 2016. An updated evaluation of reported no-observed adverse effect levels for chrysotile asbestos for lung cancer and mesothelioma. Crit Rev Toxicol 46(7):561-586; doi: 10.3109/10408444.2016.1150960.

Cowan DM, Maskrey JR, Fung ES, Woods TA, Stabryla LM, Scott PK, Finley BL. 2016. Best-practices approach to determination of blood alcohol concentration (BAC) at specific time points: Combination of ante-mortem alcohol pharmacokinetic modeling and post-mortem alcohol generation and transport considerations. Regul Toxicol Pharmacol 78:24–36.